Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
Shows & Panels
European regulators reject Pfizer arthritis drug
Thursday - 4/25/2013, 6:08pm EDT
NEW YORK (AP) -- Pfizer Inc. said Thursday that the European Union's committee of medical experts has rejected the company's drug Xeljanz for patients with rheumatoid arthritis.
The European Medicines Agency committee recommended against approving the drug because its benefits did not sufficiently outweigh its risks, Pfizer said in a statement.
The New York-based drugmaker said it would appeal the decision.
According to Pfizer, the regulators did not believe the drug consistently controlled the disease or reduced joint damage. The company also said the committee raised concerns about infections, holes in the intestines and tumors seen in patients.
The Food and Drug Administration approved Xeljanz for treating rheumatoid arthritis last November.
Shares of Pfizer fell 87 cents, or 2.9 percent, to $29.39 in after-hours trading, after closing earlier at $30.26.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.